3 Day Yeast Infection Treatment for Women, 3 Miconazole Ovule Inserts & External Monistat Anti-Itch Cream Bundle

WHO TO USE: Before using this product read the enclosed consumer information leaflet for complete directions and information. Adults and Children 12 Years of Age and Over: Vaginal Insert: With a disposable applicator place the insert into the vagina at bedtime. Throw applicator away after use. External Cream: Squeeze a small amount of cream onto your fingertip. Apply the cream onto the itchy, irritated skin outside the vagina. Use 2 times daily for up to 7 days, as needed. Children Under 12 Years of Age: Ask a doctor. Store at 20-25 degrees C (68-77 degrees F). Special Feature: Clinically Proven Ingredients: Active: Miconazole Nitrate (200 Mg In Each Applicator), Miconazole Nitrate 2% (External Cream). Inactive: Vaginal Insert: Gelatin, Glycerin, Hydrogenated Vegetable Oil Base, Titanium Dioxide. External Cream: Benzoic Acid, Cetyl Alcohol, Isopropyl Myrstate, Polysorbate 60, Potassium Hydroxide, Propylene Glycol, Purified Water, Stearyl Alcohol. • Monistat 3-Day is an effective yeast infection treatment for women, helping to reduce symptoms associated with yeast infections such as external irritation, itching, and discomfort • Monistat Instant Itch Relief Cream is an effective anti-itch cream for women, cooling and soothing irritated skin to provide long-lasting relief • Monistat vaginal ovule combination pack relieves yeast infection symptoms 4x faster than the leading prescription pill*; pack includes external Monistat anti-itch cream • Monistat Ovule Treatment contains 3 ready-to-use ovule inserts in a disposable, contoured applicator; each Monistat ovule contains 200 mg miconazole nitrate, a clinically proven safe and effective yeast infection treatment • Monistat is the number 1 gynecologist-recommended brand over the counter product in the vaginal anti-fungal category in the US among OB/GYNs** • *Based on clinical study of Monistat 1-Dose Ovule Combination Pack versus fluconazole 150 mg tablet; **According to the ProVoice Survey, fielded to US/OB-GYNs from 12/1/21-11/30/22